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ABSTRACT 
Background: Burkitt lymphoma (BL) is the commonest childhood cancer in Ghana, 
where the endemic variant is the predominant subtype and historically presents as a 
highly chemo-sensitive jaw tumor. This study aimed to update the current 
epidemiological characteristics of childhood BL in our institution. 
Procedure: Patient data for all children diagnosed with BL and seen at Korle Bu 
Teaching Hospital between January 2007 and December 2012 were retrospectively 
analyzed.  
Results: BL was diagnosed in 173 children (< 13 years) during the study period, 
with the abdomen as the most common tumor site (46%) followed by the jaw 
(31%). Abdominal tumors were associated with advanced/disseminated disease 
(p=0.002), and were more likely to occur in females irrespective of tumor stage 
(Relative risk= 1.56 [95% CI; 1.1–12.3]). Twenty-five percent (43/173) of the study 
cohort died and mortality was influenced by increasing age (p=0.02) and 
advanced disease (p=0.03). Treatment delay was experienced by 9 in 10 patients 
primarily due to familial financial constraint (75%). Treatment abandonment 
was observed as a first event in 94% of patients and two-thirds of children in the 
study were eventually lost to follow up.  
Conclusion: The predominance of primary abdominal tumors in our study 
cohort may indicate a changing epidemiological pattern of BL in Ghana. High 
rates of treatment delay and abandonment were evident and are likely to be 
contributing factors to the poor childhood cancer survival outcomes seen in 
resource limited countries in Africa. 
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INTRODUCTION 
Burkitt lymphoma (BL) is a highly aggressive B-cell malignancy characterized 
by its hallmark c-myc oncogene translocations [1-2], and classified broadly into 3 
subtypes based on distinct variations seen in malaria-endemic and non-endemic regions: 
endemic (African), sporadic (non-endemic) and immunodeficiency-associated BL [3-4]. 
The endemic variant is found within the “lymphoma belt” of equatorial Africa, an area 
extending 10–15o north and south of the equator, which corresponds to regions where 
malaria is holoendemic [5–6]. 
Epstein-Barr Virus (EBV) and plasmodium falciparum malaria infection are known to 
be important co-factors in the pathogenesis of endemic BL [3,7-8]. In countries within 
the lymphoma belt, EBV infection is documented to occur much earlier in childhood 
[9], and the virus genome isolated in almost 100% of tumor cells unlike the sporadic 
and immunodeficiency-associated variants, where EBV is detected in approximately 15-
40% of cases [8, 10]. Although a causal association between EBV and endemic BL is 
recognized, the precise mechanism by which malaria infection and EBV reactivation 
interact to promote oncogenesis remains poorly understood. Malaria-induced lytic EBV 
reactivation and polyclonal B-cell proliferation has been linked to an increased 
likelihood of chromosomal translocations that deregulate the c-myc oncogene and 
predispose to tumorigenesis. It has also been proposed that malaria co-infection impairs 
EBV-specific T-cell immunity as a cause or outcome of enhanced EBV replication, 
leading to a loss of viral control [11]. 
Endemic BL (eBL) represents 50-75% of all childhood malignancies in sub-Saharan 
Africa [12], classically presenting as facial tumor(s) that involve either the jaw or retro-
orbital space, while primary abdominal disease is less common [2,13].  
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The current epidemiology of eBL in Ghana is based on historical data collected during 
the Burkitt Tumor Project (BTP) from 1968-1996. This was a collaborative research 
endeavor between the Ghanaian government and the National Institutes of Health 
(NIH), USA, with its head office located at the department of child health in Korle Bu 
Teaching Hospital (KBTH), Accra, Ghana. Initial findings of the project suggested a 
male predominance with a peak age at presentation of 6-8 years, similar to Uganda and 
Malawi [3,12]. A ten-year prospective study (1969-1979) revealed facial tumors to be 
the most common clinical presentation in the country followed by abdominal tumors 
[14]. However, this clinical pattern demonstrated an unexplained reversal in incidence 
by the early 1980s [15]. Assessment of the geographical distribution of childhood BL in 
Ghana indicated a non-random temporal pattern, with the majority of cases residing in 
the southern-most parts of the country. This was attributed to variability in access to 
medical care as well as physician interest in diagnosis of BL [16]. 
Recent case reviews have shown eBL to still be the most common childhood cancer in 
Ghana, though its proportion in relation to other pediatric cancers has steadily declined 
over time. In the 1990s, two-thirds of all childhood cancers seen at our institution were 
lymphomas with BL making up over 90% of them [17]. In the past 10 years there has 
been a decline in the prevalence of childhood lymphomas, dropping to 31% and BL 
making up 22% of all childhood cancers [18]. 
Little information exists in either local or international literature about the current 
clinical pattern of childhood BL in West African countries such as Ghana. We therefore 
aimed to retrospectively review all children with BL seen at the pediatric oncology unit 
of our institution over a 6-year period to evaluate its epidemiological characteristics. 
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METHODS 
Study setting 
Ghana is a lower middle-income country in West Africa with a population of 25 million 
and approximately 40% of its inhabitants are aged 0-14 years. Although there is a 
government-administered National Health Insurance Scheme (NHIS) available to the 
general population, it does not cover childhood cancers and families are required to pay 
“out-of-pocket” for chemotherapy and other treatment related expenses. 
KBTH is the largest government-funded hospital in Ghana. It is located in the national 
capital of Accra and serves as a major tertiary referral center for cases from all regions 
of the country. It is also home to one of only two pediatric oncology units in Ghana. 
Approximately 125 new oncology cases are seen per year at the unit, encompassing a 
wide array of solid tumors and hematological malignancies [18]. There is no national 
cancer registry for the country, making it difficult to accurately estimate national 
pediatric cancer incidence. 
Basic laboratory tests for cancer diagnostic work up are readily available at KBTH. 
However, most of these tests are not covered by the NHIS and pose a serious financial 
burden for many patients. Immunophenotyping and cytogenetic studies are currently 
unavailable in KBTH and EBV serology is not routinely performed as part of the BL 
diagnostic workup in our unit.  
 
Subject selection criteria and Data collection 
All children (< 13 years) with BL confirmed by histology/cytology and diagnosed 
between January 1st, 2007 and December 31st, 2012 were included. 
Patient demographic and clinical information were obtained from their medical records 
and the Pediatric Oncology Network Database (POND) archive, which is a free access 
 7 
online database located in the unit and designed by St. Jude’s Children’s Research 
Hospital in Memphis, Tennessee, USA, to facilitate hospital-based cancer registration in 
resource limited countries [19]. Information on age, gender, place of residence, primary 
caregiver/guardian occupation and educational attainment, HIV status, tumor site, 
baseline disease staging, and disease outcome were obtained. Both educational 
attainment and occupation of the primary caregiver/guardian were used as proxy 
measures for socioeconomic status (SES) and have previously been validated as reliable 
surrogates for SES in neighboring west African countries [20]. Treatment abandonment 
was defined as the failure to attend hospital for prescribed chemotherapy within 28 days 
or a post-treatment follow up appointment within 3 months while treatment delay was 
said to have occurred if chemotherapy was not initiated within 48 hours of a diagnostic 
confirmation of BL. Patients who had missing data on abandonment and cause of 
treatment delay were excluded from the final analysis. 
Staging of disease was done using the St. Jude/Murphy classification [21]. Stages I & II 
constituted localized disease with stages III & IV representing advanced disease. 
Chemotherapy treatment was administered based on local protocol and staging 
(Supplemental Table S1).  
 
Statistical analysis 
Data were summarized and expressed as means and standard deviations for continuous 
variables and percentages for categorical variables. Chi-square and Fisher’s exact test 
were used to evaluate proportional differences while student t-test and ANOVA were 
used to assess differences in means. Relative risk was calculated using the Mantel 
Haenszel method. All level of significance was considered as p<0.05. Data analysis was 
performed using SPSS version 20.0.  
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RESULTS 
 
Patient Characteristics 
There were 173 children in the study cohort [Table 1] with a mean age of 6.9 (± 2.7) 
years at diagnosis. No significant gender difference was observed in age at diagnosis 
[Table 2], though males presented at a slightly older age than females (7.2 years vs 6.4 
years, p= 0.09). Only 29% of primary caregivers/guardians had attained a secondary 
level education or above while almost 50% had no formal education [Table 1]. The 
majority of parents were employed in low income jobs such as subsistence farming and 
petty trading [Table 1]. 
A large proportion of patients (139/173) resided outside of the Greater Accra region – 
where our pediatric oncology unit is located – and some families from the Northern 
region had to travel up to 600 kilometers (373 miles) to receive treatment at our 
institution [Supplemental Figure S1]. All 104 patients with available information on 
HIV serology tested negative. 
 
Tumor Characteristics 
Primary abdominal tumor was the most common clinical presentation [Table 1]. There 
was a male predominance for jaw tumors [Fig. 1], and males aged 0-4 years were more 
likely to present with a jaw tumor compared to other sites (Relative Risk = 1.32 [95% 
CI; 1.10 – 15.33]) while females were more likely to present with an abdominal tumor 
even after adjusting for age and tumor stage (Relative Risk = 1.56 [95% CI; 1.07 – 
12.28]). Facial tumors were most common in the 5–9 years group [Table 2]. The 
majority of patients presented with advanced/disseminated disease [Table 1], which was 
strongly associated with abdominal disease (p = 0.002). 
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 Outcomes 
Table 3 outlines the factors contributing to delays and abandonment of treatment. 
Treatment delay was marginally longer for advanced disease compared to localized 
tumors with lack of funds being the most significant contributor. Abandonment of 
treatment was nearly universal and abandonment rate did not differ by disease stage. 
Two-thirds of children in the study were lost to follow up during treatment and 44 
(25%) were confirmed to have died during the study period. There was no significant 
difference in mortality between males and females (p= 0.54). All deaths occurred in 
children with advanced/disseminated disease and mortality was found to be 
influenced by increasing age and advanced disease [Table 4]. 
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DISCUSSION 
This study updates the clinical pattern of childhood BL in Ghana first described in our 
institution over 40 years ago and highlights some of the challenges faced by resource 
limited countries in achieving good treatment outcomes for common childhood cancers. 
Some limitations to our study findings are centered on its retrospective analysis of 
historical hospital-based records which had some missing or incomplete data. 
Furthermore, due to a lack of appropriate patient contact information, we were unable to 
trace children who had defaulted treatment to determine their disease progression or 
survival status. This limited our ability to accurately comment on BL-associated 
survival rates for our cohort. Data were not collected on children who subsequently 
resumed treatment after initial attrition and so the true impact of treatment abandonment 
on disease outcome(s) in our study is unknown. The relatively small sample size did not 
permit more robust statistical analysis and there is a possibility that some of our study 
findings may be due to chance.  
Despite these limitations, it is of interest to note that while the patient demographics for 
childhood BL in our institution has remained mostly unchanged since the 1960s, there 
has been a striking transformation in the clinical presentation of disease from the 
characteristic facial tumor to a predominantly abdominal tumor pattern. 
This change has corresponded with a reduction in BL incidence. Approximately 29 
cases of BL per year were diagnosed during the study period, representing a 30% 
reduction compared to figures from the BTP three decades ago [22]. This decline could 
be due to a reduced exposure of Ghanaian children to malaria as a result of enhanced 
control measures with Insecticide Treated Nets (ITNs) combined with improved 
urbanization and socioeconomic status of the average Ghanaian [23-24]. Malaria 
prevention measures within the lymphoma belt have already been shown to significantly 
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lower the risk of BL [25]. However, a possible artefact explanation for this decline is 
the failure to capture undiagnosed cases of BL in the community due to poor parental 
health-seeking behavior for childhood cancers in Ghana [26]. In addition, the 
establishment of a second pediatric oncology unit in the country at the Komfo Anokye 
Teaching Hospital (KATH) in Kumasi has likely led to a reduction in the case referral 
rate to our hospital. An 8-year retrospective study from KATH estimated their annual 
BL case rate at 78 cases per year, although this represented both clinically suspected 
and histologically proven BL [27]. Our study highlights the necessity of a national 
cancer registry in Ghana for accurate estimation of cancer incidence.  
Though facial/jaw tumors are the hallmark feature of eBL, we observed a shift towards 
predominantly abdominal tumors in patients seen at our hospital. This mirrors findings 
documented by the BTP in the 1970s, when a sudden and unexplained rise in the 
proportion of children presenting with abdominal tumors was noticed [15]. The advent 
of routine radiological imaging as part of the diagnostic workup for children presenting 
with solid tumors to our unit may offer a plausible explanation for this change as 
historical cases were not systematically subjected to the same rigorous investigations for 
tumor localization and autopsies were not regularly performed on children who died 
from BL prior to treatment [14]. It is possible that the historical burden of abdominal 
tumors has been underestimated. However, it would be expected that the introduction of 
routine imaging at our hospital as a standard procedure for tumor staging would 
correspond to an increase in the proportion of children diagnosed with combined 
facial/jaw and abdominal tumors and not just solitary abdominal disease. Similarly, 
while the predominance of advanced disease in our cohort may also offer an alternative 
explanation due to extensive tumors involving the abdomen, a higher proportion of 
cases with both abdominal and facial/jaw tumors should also have been noted. We 
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hypothesize that there has been a reduction in the incidence of BL from an endemic 
pattern to a level intermediate between endemic and sporadic BL (sBL). Though this 
cannot be definitively concluded from this study, similar findings have been observed in 
east and west African regions previously considered to have a predominantly endemic 
variant of disease [7, 28]. Our study finding raises an issue of the necessity for an 
accurate and globally accepted definition of endemic versus sporadic BL. While these 
terms were historically used to describe the epidemiological distribution of BL, the 
solitary use of geographic location and/or clinicopathological features as descriptive 
delineators for these variants has been called into question [29]. The longstanding 
association of endemic and sporadic BL with jaw/facial and abdominal tumors 
respectively has led to these variants being considered synonymous with these tumor 
patterns. This is especially true in the lymphoma belt, where diagnosis often relies on 
clinical presentation with a jaw tumor and findings from fine needle aspirate cytology 
(FNAC) [30]. The risk of diagnostic misclassification becomes even more acute in cases 
of abdominal tumors due to the overlapping similarities in the morphological 
appearance of endemic and sporadic BL on FNAC. [31] While recent advances in 
molecular studies have led to the identification of subtle but distinct differences in the 
breakpoint pattern of c-myc/IgH gene translocation for eBL and sBL [32], the lack of 
cytogenetic studies, genomic sequencing and tests for EBV detection in tumor samples 
in resource limited countries within the lymphoma belt impedes diagnostic certainty. 
The question of whether all childhood BL within the lymphoma belt should be 
considered endemic and if not, what specific feature(s) should define it, remains to be 
addressed for us to fully interpret the implications of our study finding.  
We observed similarities with the historical pattern of geographic distribution for 
children with BL first observed at our hospital in the 1970s [16]. Our findings 
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underscore previous observations that most children with BL reside in the southern half 
of the country, with most cases dwelling in the Eastern region. This sharply contrasts 
with a recent study at KATH in the Ashanti region of Ghana, which found that majority 
of cases seen at their facility were residents of the Ashanti and Western regions of the 
country [27]. This discrepancy in geographic distribution of cases is most likely due to 
bias in proximity and access to medical facilities. Previously, all cases of childhood BL 
were referred to our hospital from other regions in the country due to health worker 
awareness of the BTP, which was known to cover all medical costs pertaining to 
treatment and transportation of patients to and from their home villages [16]. The 
conclusion of the project, together with the establishment of an alternative oncology 
treatment center has probably led to significant reduction in the referral rate of BL cases 
to our hospital from regions that are closer in proximity to the Ashanti region. As seen 
in other countries [25, 33-34], the incidence and distribution of malaria in Ghana might 
offer a clue to the possible spatial dispersion of childhood BL. However, available data 
on geographic variations of malaria transmission in Ghana are conflicting making it 
difficult to draw any conclusions to this regard.  
Occupational status and educational attainment of the parents/guardians were used as 
proxies for socioeconomic status (SES) in this study and most patients belonged to a 
low SES. Though the impact of SES on the distribution and clinical characteristics of 
BL is still unclear, poverty is associated with an early age at primary EBV infection [28, 
35], and is likely to influence health-seeking practices, affordability of treatment and 
compliance. SES should be considered as a surrogate indicator for exposure to factors 
believed to play an etiological role in BL. It may also be associated with a poor defense 
response toward environmental exposures due to poor nutrition, poor hygienic 
conditions, and an increased risk of malaria as a result of poor housing [12]. 
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The strong association between facial/jaw tumors and males aged 0-4 years has also 
been observed in numerous studies [7, 34-36], suggesting gender differences in 
exposure to factors that influence tumorigenesis which likely wane with increasing age 
[7].  
Our study highlights the multifactorial influence on outcomes of cancer treatment often 
observed in resource-limited countries. Many studies have outlined the risk factors for 
poor prognosis of BL, such as advanced disease and abdominal tumors [37-38]. 
Approximately 90% of children in our study presented with advanced/disseminated 
disease, which was strongly associated with abdominal tumors.  
Factors known to adversely affect BL treatment outcome such as low SES, distance of 
residence from referral hospital, inadequate treatment support measures, and poor 
patient compliance [26, 39] were all present in our study. Although treatment 
abandonment in our study cohort was much higher than rates of up to 67% documented 
for childhood cancers in other resource limited countries [40], the fact that 76% of 
children managed for BL at our hospital did not reside in the Greater Accra region, 
where our facility is located, might explain why a significant proportion abandoned 
treatment and were eventually lost to follow up. Low SES was observed to be a 
predictor of treatment delay for our study cohort which corroborates previous findings 
that high treatment abandonment rates in developing countries are a major cause of 
therapeutic failure and adverse outcomes in childhood cancers [40].  
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LEGENDS 
TABLE 1 Characteristics of children (< 13 years) diagnosed with BL at the pediatric 
oncology unit, KBTH (2007 – 2012) 
TABLE 2 Gender and primary tumor site categorized by age group at diagnosis for 
children diagnosed with BL at the pediatric oncology unit, KBTH (2007 – 
2012) 
 
TABLE 3 Treatment delays and abandonment rates for children diagnosed with BL at 
the pediatric oncology unit, KBTH (2007 – 2012) 
 
TABLE 4 Survival outcomes for all children (< 13 years) diagnosed with BL at the 
pediatric oncology unit, KBTH (2007 – 2012) 
 
FIGURE 1 Graph of the gender distribution of BL by tumor site for children diagnosed 
with BL at the pediatric oncology unit, KBTH (2007 – 2012) 
 
SUPPLEMENTAL TABLE S1 Local chemotherapy protocol for treatment of endemic 
BL at KBTH 
 
SUPPLEMENTAL FIGURE S1 Map of Ghana illustrating the geographic distribution 
of children diagnosed with BL at the pediatric 
 22 
oncology unit, KBTH (2007 – 2012) by region of 
residence 
 
 
TABLE 1:  Characteristics  of  children  (<  13  years)  diagnosed  with  BL at  the  pediatric
oncology unit, KBTH (2007 – 2012)
Study Co-variates                                                          N (%)
Gender                        Male                                   
Female
105 (61)
68 (39)
Age group 0 – 4
5 – 9 
≥ 10
32 (19)
104 (60)
37 (21)
Parental Occupation Professional/Managerial
Subsistence farmer
Petty trader
Artisan
Unemployed
17 (10)
54 (31)
52 (30)
34 (20)
16 (9)
Education of primary
caregiver
None
Primary
Secondary
Tertiary
75 (43)
50 (29)
31 (18)
17 (10)
Tumor site Jaw
Abdomen
Jaw & Abdomen
Systemic
54 (31)
79 (46)
37 (21)
3 (2)
Disease stage Localized (stages I – II)
Disseminated/Advanced (stages III – IV)
20 (12)
153 (88)
Survival outcome Alive
Dead 
Lost to follow up
11 (6)
44 (25)
118 (69)
TABLE 2: Gender and site of primary tumor for the study cohort categorized by age group at
diagnosis.
0 – 4 years
(n = 32)
5 – 9 years
(n = 104)
 10 years
(n = 37)
        P
Gender
Boys    16      67      22
       0.34Girls    16      37      15
Tumour site
Jaw     14      31      9      
       0.40
     
      
Abdomen     10      48      21
Jaw + Abdomen     7      24      6
Systemic     1       1      1
TABLE 3: Treatment delays and abandonment rates for children diagnosed with BL at the pediatric
oncology unit, KBTH (2007 – 2012)
       All
  (N = 147)
Localized 
(n = 20)
Advanced
(n = 127)
  p-value
Treatment delay (%)
Febrile Neutropenia 37 (25) 7 (35)     30 (24)     0.28†Lack of funds 110 (75) 13 (65)     97 (76)
Days of treatment delay (± SD)
All
Febrile Neutropenia
7.0 ± 2.7
7.2 ± 2.7
7.1 ± 1.8
7.0 ± 1.9
7.5 ± 2.2
7.3 ± 2.4
7.7 ± 2.2
    
    0.89¶
Lack of funds 7.8 ± 2.0 6.9 ± 1.5
Other 6.0 ± 1.0                           
Abandoned treatment (%) 138 (94) 20 (100) 118 (93)      0.24†
  Keys: ¶ = ANOVA test;  † = Chi-square test;   SD = standard deviation
TABLE 4: Survival outcomes for all children (< 13 years) diagnosed with BL at the pediatric 
oncology unit, KBTH (2007 – 2012)
          Alive
        (n = 11)
      Died 
    (n = 44)
Lost to follow up          P
      (n = 118)
Age (in years)
0 - 4                -           4             28
5 - 9                3          35             66                    0.02
≥ 10                8           5             24
Gender         
Boys                8           25             72 0.54Girls                3           19             46
Disease stage
Localized (stages I-II)                9             -             11
0.03
Advanced (stages III-IV)                2            44             107
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LOCAL CHEMOTHERAPY PROTOCOL FOR TREATMENT OF ENDEMIC 
BURKITT LYMPHOMA ACCORDING TO TUMOUR STAGING AT KORLE BU 
TEACHING HOSPITAL, ACCRA, GHANA.  
Tumor 
Stage
Course of Treatment
Stage I & II
4 courses of IV Cyclophosphamide 40mg/kg every 2 weeks with 
intrathecal (IT) Methotrexate for central nervous system (CNS) 
prophylaxis during courses 1-3.
Stage III
A pre-phase dose of IV Cyclophosphamide 1400mg/m2 with IT 
Methotrexate, followed by a combination chemotherapy consisting of 6 
cycles (Cyclophosphamide, Vincristine and Doxorubicin alternating with 
Cyclophosphamide, Vincristine and Cytarabine every 2 weeks) with IT 
Methotrexate given during the first 3 courses
Stage IV
For bone marrow involvement a modified version of a mature B-cell 
protocol for high income countries without Rituximab is used, and 
inclusive of four cycles of maintenance therapy, following reduction, 
induction and consolidation phases of therapy. For CNS disease, additional 
intrathecal therapy is included until cerebrospinal fluid (CSF) cytology is 
negative
1
2
3
4
